A detailed history of Apis Capital Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Apis Capital Advisors, LLC holds 77,000 shares of VKTX stock, worth $3.26 Million. This represents 5.41% of its overall portfolio holdings.

Number of Shares
77,000
Previous 100,000 23.0%
Holding current value
$3.26 Million
Previous $5.3 Million 8.06%
% of portfolio
5.41%
Previous 4.93%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $1.15 Million - $1.62 Million
-23,000 Reduced 23.0%
77,000 $4.87 Million
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $1.42 Million - $2.41 Million
30,000 Added 42.86%
100,000 $5.3 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $348,000 - $1.89 Million
-20,000 Reduced 22.22%
70,000 $5.74 Million
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $535,920 - $1.14 Million
-58,000 Reduced 39.19%
90,000 $1.67 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $1.62 Million - $2.37 Million
148,000 New
148,000 $1.64 Million
Q4 2020

Feb 16, 2021

SELL
$5.3 - $6.71 $477,000 - $603,900
-90,000 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$6.55 - $8.6 $281,650 - $369,800
-43,000 Reduced 32.33%
90,000 $619,000
Q2 2019

Aug 13, 2019

SELL
$7.67 - $10.63 $130,390 - $180,710
-17,000 Reduced 11.33%
133,000 $1.1 Million
Q1 2019

May 07, 2019

BUY
$7.58 - $9.94 $227,400 - $298,200
30,000 Added 25.0%
150,000 $1.49 Million
Q4 2018

Feb 14, 2019

BUY
$7.16 - $16.21 $859,200 - $1.95 Million
120,000 New
120,000 $918,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Apis Capital Advisors, LLC Portfolio

Follow Apis Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Apis Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Apis Capital Advisors, LLC with notifications on news.